CereScan Recognized as One of Angel Capital Summit’s Most Promising Companies

Share Article

The nation’s leader in brain diagnostics creates a buzz among attendees, taking home third place in the “Venture Bucks” contest

CereScan, the nation’s leader in providing statistically measured brain diagnostics, announced today it was recognized as one of the most promising companies at the 2016 Angel Capital Summit in Denver. The Rockies Venture Club’s annual conference attracted more than 300 investors and entrepreneurs and 23 presenting companies.

As part of the summit, attendees were each given $100,000 in “Venture Bucks” to invest in the presenting companies of their choosing. CereScan received the third highest amount of Venture Bucks with $1.5 million, falling closely behind mTusker with $1.56 million and Unboundly with $1.7 million.

*****

“It is an honor to receive this recognition from prominent members of the Colorado business community and to be included among companies at the forefront of innovation,” said Rick Fort, PhD, Chief Science Officer at CereScan, who presented at the summit. “This vote of confidence is a testament to the incredible momentum CereScan has achieved and fuels our passion to continue to provide the best in brain diagnostics.”

The Angel Capital Summit brings together early-stage companies and the investors who may potentially support them. More than 80 startups applied to pitch at the two-day event and only 23 were selected.

Each company was given ten minutes to present. The pitches were interactive with audience feedback on the quality of the deal, the management team, market opportunity and the pitch itself. Company representatives receive feedback to let them know their strengths and areas for development.

*****

“We are thrilled to be featured at the 2016 Angel Capital Summit and to highlight the role our brain imaging and database can play in value-based medicine,” said John Kelley, CEO and Chairman of CereScan. “Our data analytics will provide practitioners with real-time brain image analysis and quantitative measurements to assist in the diagnosis and care of sophisticated brain disorders.”

CereScan is a functional brain imaging and analytics company that includes what is believed to be the country’s largest and most complete functional brain imaging data warehouse. The CereMetrixTM database unites the company’s brain imaging with vital medical data to give practitioners access to the information needed to make better, faster diagnostic decisions for complex brain conditions.

CereScan is the nation’s leader in providing statistically measured brain diagnostics based on a new generation of imaging software, PET/CT (Positron Emission Tomography/Computed Tomography) and qSPECT (Quantitative Single Photon Emission Computed Tomography) neuroimaging technologies. Referring and treating medical experts can rely on CereScan to offer differentiated diagnoses on a wide array of brain-based disorders including:

  •     Traumatic Brain Injury
  •     Toxic Brain Injury
  •     Alzheimer’s Disease
  •     Mild Cognitive Impairment
  •     PTSD
  •     Other Dementias
  •     Parkinson’s Disease
  •     Obsessive Compulsive Disorder
  •     Bipolar Disorder
  •     ADD/ADHD
  •     Anxiety Disorder

About CereScan

CereScan combines state-of-the-art SPECT and PET/CT brain imaging technologies with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the neurological basis of their conditions. In a variety of legal settings, CereScan provides objective evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit http://www.CereScan.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John Kelley

Gail McClurg
@CereScan
Follow >